Internal Medicine, Hematology & Oncology · Tampa, FL
NPI
1215390687
Since 2016
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
2 Tampa General Cir Fl 3
Tampa, FL, 33606
Phone (813) 844-7585
Groups this clinician bills Medicare through
Medicare paid, 2024
$18K
235 services
Medicare patients, 2024
58
Average age 72
Drug cost, 2024
$2.5M
299 prescriptions
Company payments, 2025
$96K
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nikesh N Shah was code 99232 (hospital e&m - subsequent), 71 times for 28 patients. In total Nikesh N Shah billed 235 services in 20 codes, and Medicare paid $18K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-10-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 71 | 28 | $60.55 | $4,299 |
| 99233 Hospital E&M - Subsequent | Facility | 59 | 24 | $92.00 | $5,428 |
By year: 2022 $8,226 for 135 services; 2023 $17K for 722 services; 2024 $18K for 235 services.
Medicare prescription drug claims, 2024
In 2024, the drug Nikesh N Shah prescribed most often to Medicare patients was Iclusig (Ponatinib Hcl), with 36 prescriptions and refills. In total Nikesh N Shah wrote 299 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Iclusig Ponatinib Hcl | 36 | 36 | Under 11 | $789K |
| Acyclovir Generic | 28 | 32 | 12 | $191 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 13 | 13 | Under 11 | $26.56 |
| Atovaquone Generic | 12 | 15 | Under 11 | $6,891 |
| Zelboraf Vemurafenib | 12 | 12 | Under 11 | $97K |
| Cotellic Cobimetinib Fumarate | 12 | 12 | Under 11 | $89K |
Brand drugs: 143 claims; generic drugs: 156 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nikesh N Shah $96K ($96K in general payments such as food, travel and fees) from 14 companies. The largest payer was Jazz Pharmaceuticals Inc. with $27K.
| Company | Payments | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. JAZZ | 23 | $27K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 17 | $24K |
| Amgen Inc. AMGN | 20 | $19K |
| Genentech USA, Inc. ROG.SW | 20 | $17K |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $3,709 |
| AstraZeneca Pharmaceuticals LP AZN | 4 | $3,341 |
| Celgene Corporation BMY | 5 | $170 |
| Abbvie Inc. ABBV | 2 | $139 |
| Adaptive Biotechnologies Corporation ADPT | 1 | $102 |
| BeOne Medicines USA, Inc. ONC | 1 | $94.57 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.